Myeloma Canada is pleased to share that funding for Sarclisa (isatuximab) is officially available in two more provinces, British Columbia and Ontario! Sarclisa (isatuximab) was listed for reimbursement by both provinces in combination with pomalidomide (Pomalyst) OR carfilzomib (Krypolis), AND dexamethasone.

 

With Quebec and Alberta having announced reimbursement for Sarclisa earlier this year, BC and Ontario’s recent changes bring the total number of provinces with access to isatuximab up to 4, as at July 1st 2023!

 

IN ONTARIO:

Funding for isatuximab in combination with carfilzomib (+ dexamethasone) is provided through the New Drug Funding Program. For more information click here.

 

Funding for isatuximab in combination with pomalidomide (+ dexamethasone) is provided through the New Drug Funding Program and the Exceptional Access Program. For more information click here.

 

IN BRITISH COLUMBIA:

isatuximab + carfilzomib + dexamethasone, AND isatuximab + pomalidomide + dexamethasone are both reimbursed under ‘Restricted Funding’ and will require completion of the BC Cancer Compassionate Access Program Application.  For more information click here.